NYKD Nykode Therapeutics AS

0.2829USD2.735 NOK · OSL-0.18%Mkt Cap: 110.76M USDP/E: —

Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies for the treatment of cancer and autoimmune diseases. The company develops vaccines for the treatment cancer…

Institutional holders10 on file

Key Statistics

Company
Market Cap110.76M USD
Enterprise Value87.92M USD
Revenue (TTM)464.00K USD
Gross Profit464.00K USD
Net Income (TTM)-12.24M USD
Revenue/Share0.0010 USD
Last Price0.2829 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees59
CountryNO
SectorHealthcare
IndustryBiotechnology
ISINNO0010714785
Valuation
P/E (Trailing)—
P/E (Forward)-9.98
PEG—
EV/EBITDA-31.56
EV/Revenue189.49
P/S2307.93
P/B1.19
EPS (TTM)-0.59 USD
EPS (Forward)-0.27 USD
52W Range
0.212922% of range0.5347
52W High0.5347 USD
52W Low0.2129 USD
Profitability
Gross Margin100.00%
Oper. Margin-5958.40%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-13.37%
ROA-12.25%
ROIC-57.77%
ROCE-30.49%
Growth
Revenue Growth-46.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-29.46M USD
CapEx (TTM)38.00K USD
FCF Margin-3421.66%
FCF Yield-14.33%
Net Debt-43.01M USD
Net Debt/EBITDA1.60
Net Debt/FCF—
Balance Sheet
Debt/Equity0.03
Current Ratio11.52
Quick Ratio11.52
Book Value/Sh2.30 USD
Cash/Share0.14 USD
Dividends
Fwd Div Rate0.10 USD
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div DateMay 27, 2025
Pay Date—
Analyst Consensus
Rating—
Target (Mean)0.7757 USD
Upside (mean)+174.2%
Target Range0.5689 USD – 1.034 USD
0.5689+174.2% to mean1.034
# Analysts3
Ownership
Shares Out.391.55M
Float232.84M
Insiders36.44%
Institutions19.08%
Technical
SMA 500.3471 (-18.5%)
SMA 2000.3445 (-17.9%)
Beta1.02
S&P 52W Chg12.00%
Avg Vol (30d)849.70K
Avg Vol (10d)675.01K
Technical Indicators
RSI (14)28.4
MACD-0.1547
MACD Signal-0.1506
MACD Hist.-0.0041
BB Upper0.3319 USD
BB Middle0.3055 USD
BB Lower0.2791 USD
BB Width17.29%
ATR (14)0.0131 USD
Vol Ratio (20d)0.95x

About Nykode Therapeutics (OSL: NYKD)

›

Nykode Therapeutics (OSL: NYKD) is listed on Oslo Børs, where its shares trade in NOK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 59 employees.

The shares were at 2.735 NOK on 19 November 2026, up 22.2% over 52 weeks. Its 52-week range is 2.058 NOK to 5.170 NOK: the price is 47.1% below the high and 32.9% above the low.

Its market capitalisation is 1.07B NOK.

Nykode Therapeutics reports return on equity of -13.4% and revenue down 46.5% year over year.

It holds more cash than debt, a net cash position of 43.01M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. 3 analysts cover the stock; their mean price target of 7.500 NOK is 174.2% above the current price. The next earnings report is expected on 25 November 2026.